<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Execution Roadmap: ER Minoxidil Development to Human Use</title>
    <style>
        body {
            font-family: 'Arial', sans-serif;
            line-height: 1.6;
            max-width: 900px;
            margin: 0 auto;
            padding: 40px 20px;
            color: #333;
        }
        h1 {
            color: #1a73e8;
            border-bottom: 3px solid #1a73e8;
            padding-bottom: 10px;
        }
        h2 {
            color: #185abc;
            margin-top: 40px;
            border-bottom: 1px solid #ddd;
            padding-bottom: 5px;
        }
        h3 {
            color: #1967d2;
            margin-top: 25px;
        }
        h4 {
            color: #4285f4;
            margin-top: 20px;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 15px 0;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 10px 12px;
            text-align: left;
        }
        th {
            background-color: #e8f0fe;
            font-weight: bold;
            color: #185abc;
        }
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        .phase-box {
            background-color: #e8f0fe;
            padding: 20px;
            border-left: 4px solid #1a73e8;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }
        .success-box {
            background-color: #e6f4ea;
            padding: 15px;
            border-left: 4px solid #34a853;
            margin: 20px 0;
        }
        .warning-box {
            background-color: #fef7e0;
            padding: 15px;
            border-left: 4px solid #f9ab00;
            margin: 20px 0;
        }
        .danger-box {
            background-color: #fce8e6;
            padding: 15px;
            border-left: 4px solid #d93025;
            margin: 20px 0;
        }
        .checklist {
            list-style: none;
            padding-left: 0;
        }
        .checklist li {
            padding: 8px 0 8px 35px;
            position: relative;
            border-bottom: 1px solid #eee;
        }
        .checklist li:before {
            content: "☐";
            position: absolute;
            left: 5px;
            font-size: 18px;
        }
        .checklist li.critical:before {
            content: "⚠️";
        }
        ul, ol {
            margin: 10px 0;
            padding-left: 25px;
        }
        li {
            margin: 5px 0;
        }
        hr {
            border: none;
            border-top: 1px solid #ddd;
            margin: 30px 0;
        }
        .timeline {
            background-color: #f8f9fa;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
        .cost {
            color: #137333;
            font-weight: bold;
        }
        .provider-card {
            background-color: #fff;
            border: 1px solid #ddd;
            border-radius: 8px;
            padding: 15px;
            margin: 10px 0;
        }
    </style>
</head>
<body>

<h1>Execution Roadmap</h1>
<h2 style="border: none; margin-top: 0;">From Formulation to Human Use</h2>

<p><strong>Date:</strong> February 5, 2026</p>
<p><strong>Product:</strong> Extended-Release Minoxidil 8.5 mg (Lipid Matrix)</p>

<div class="phase-box">
    <h3 style="margin-top: 0;">Overview: 5 Phases Before Human Use</h3>
    <table>
        <tr>
            <th>Phase</th>
            <th>Duration</th>
            <th>Cost Estimate</th>
            <th>Gate</th>
        </tr>
        <tr>
            <td>1. Formulation Development</td>
            <td>2-4 weeks</td>
            <td>$2-5K</td>
            <td>Dissolution meets spec</td>
        </tr>
        <tr>
            <td>2. Analytical & QC</td>
            <td>2-3 weeks</td>
            <td>$3-8K</td>
            <td>Methods validated</td>
        </tr>
        <tr>
            <td>3. Stability Testing</td>
            <td>1-6 months (parallel)</td>
            <td>$2-5K</td>
            <td>No degradation at 1 month</td>
        </tr>
        <tr>
            <td>4. Animal PK (Optional)</td>
            <td>4-6 weeks</td>
            <td>$30-50K</td>
            <td>PK profile acceptable</td>
        </tr>
        <tr>
            <td>5. Compounding Setup</td>
            <td>2-4 weeks</td>
            <td>$1-3K</td>
            <td>Pharmacy ready to compound</td>
        </tr>
        <tr style="font-weight: bold; background-color: #e6f4ea;">
            <td>TOTAL (without animal PK)</td>
            <td>6-10 weeks</td>
            <td>$8-21K</td>
            <td></td>
        </tr>
        <tr style="font-weight: bold; background-color: #e6f4ea;">
            <td>TOTAL (with animal PK)</td>
            <td>10-14 weeks</td>
            <td>$38-71K</td>
            <td></td>
        </tr>
    </table>
</div>

<hr>

<h2>Phase 1: Formulation Development</h2>

<div class="timeline">
    <strong>Duration:</strong> 2-4 weeks | <strong>Cost:</strong> <span class="cost">$2,000-5,000</span>
</div>

<h3>1.1 Make Test Batches</h3>

<ul class="checklist">
    <li>Source excipients (Compritol, Precirol, PEG 6000, Poloxamer 188, MCC, lactose)</li>
    <li>Source minoxidil API (USP grade)</li>
    <li>Make 3 small batches (50-100 units each) per the formulation protocol</li>
    <li>Document batch records for each</li>
    <li>Visual inspection: tablets/capsules uniform, no defects</li>
</ul>

<h3>1.2 Dissolution Testing (Critical)</h3>

<ul class="checklist">
    <li class="critical">Run dissolution on each batch (1, 4, 8, 12 hours)</li>
    <li>Compare to target: 15-20% (1h), 40-50% (4h), 65-75% (8h), >80% (12h)</li>
    <li>If too fast: increase Compritol, decrease PEG</li>
    <li>If too slow: decrease Compritol, increase PEG</li>
    <li>Iterate until dissolution meets target (may need 2-4 iterations)</li>
</ul>

<h3>1.3 Fed-State Dissolution</h3>

<ul class="checklist">
    <li>Run dissolution in FeSSIF or milk (simulates fed state)</li>
    <li>Compare to fasted state dissolution</li>
    <li>Acceptable if fed-state 4h dissolution is &lt;1.5x fasted</li>
    <li>If food effect too high: add calcium stearate or carnauba wax</li>
</ul>

<div class="success-box">
    <strong>Phase 1 Exit Criteria:</strong>
    <ul>
        <li>Dissolution meets target profile in fasted media</li>
        <li>Food effect is acceptable (&lt;1.5x at 4h)</li>
        <li>Batch-to-batch variability &lt;15%</li>
    </ul>
</div>

<hr>

<h2>Phase 2: Analytical & Quality Control</h2>

<div class="timeline">
    <strong>Duration:</strong> 2-3 weeks | <strong>Cost:</strong> <span class="cost">$3,000-8,000</span>
</div>

<h3>2.1 Assay Method</h3>

<ul class="checklist">
    <li>HPLC method for minoxidil content (or use compendial USP method)</li>
    <li>Verify method works with your matrix (lipid interference check)</li>
    <li>Run assay on 3 batches: target 95-105% of label claim</li>
</ul>

<h3>2.2 Content Uniformity</h3>

<ul class="checklist">
    <li>Test 10 individual units from each batch</li>
    <li>Calculate AV (Acceptance Value) per USP &lt;905&gt;</li>
    <li>Target: AV ≤ 15.0</li>
</ul>

<h3>2.3 Physical Tests</h3>

<ul class="checklist">
    <li>Weight variation (±5%)</li>
    <li>Hardness (tablets): 6-10 kP</li>
    <li>Friability (tablets): &lt;1.0%</li>
    <li>Disintegration: should NOT disintegrate in &lt;1 hour (it's ER)</li>
</ul>

<div class="success-box">
    <strong>Phase 2 Exit Criteria:</strong>
    <ul>
        <li>Assay: 95-105% of label claim</li>
        <li>Content uniformity: AV ≤ 15.0</li>
        <li>Physical tests pass</li>
    </ul>
</div>

<hr>

<h2>Phase 3: Stability Testing</h2>

<div class="timeline">
    <strong>Duration:</strong> Ongoing (1-6 months) | <strong>Cost:</strong> <span class="cost">$2,000-5,000</span>
</div>

<h3>3.1 Accelerated Stability</h3>

<ul class="checklist">
    <li>Place samples at 40°C / 75% RH</li>
    <li>Test at: 1 week, 2 weeks, 1 month, 3 months, 6 months</li>
    <li>Test: Appearance, Assay, Dissolution, DSC (lipid form)</li>
</ul>

<h3>3.2 Real-Time Stability</h3>

<ul class="checklist">
    <li>Place samples at 25°C / 60% RH</li>
    <li>Test at: 1 month, 3 months, 6 months, 12 months</li>
    <li>This runs in parallel - don't wait for completion</li>
</ul>

<h3>3.3 DSC/XRD Monitoring (Polymorphism)</h3>

<ul class="checklist">
    <li>Run DSC at T0 and each stability timepoint</li>
    <li>Watch for peak shifts indicating polymorphic transition</li>
    <li>If dissolution slows >15% at 1 month accelerated: investigate</li>
</ul>

<div class="warning-box">
    <strong>Minimum Before Human Use:</strong>
    <ul>
        <li>1-month accelerated stability data with no significant changes</li>
        <li>Dissolution within ±10% of initial</li>
        <li>No assay drop >5%</li>
    </ul>
    <p>You can proceed to human use after 1-month accelerated data while continuing longer stability studies.</p>
</div>

<hr>

<h2>Phase 4: Animal PK Study (Recommended but Optional)</h2>

<div class="timeline">
    <strong>Duration:</strong> 4-6 weeks | <strong>Cost:</strong> <span class="cost">$30,000-50,000</span>
</div>

<h3>4.1 Study Design</h3>

<ul class="checklist">
    <li>Species: Beagle dogs (n=6)</li>
    <li>Design: 3-way crossover (ER fasted, ER fed, IR solution)</li>
    <li>Dose: ~2-3 mg/kg (approximately 20-30 mg per dog)</li>
    <li>Washout: 1 week between periods</li>
</ul>

<h3>4.2 Sampling & Analysis</h3>

<ul class="checklist">
    <li>Blood samples: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24h</li>
    <li>Plasma separation and storage at -80°C</li>
    <li>LC-MS/MS analysis for minoxidil</li>
    <li>Calculate: Cmax, Tmax, AUC0-24, food effect ratio</li>
</ul>

<h3>4.3 Success Criteria</h3>

<ul class="checklist">
    <li>Tmax delayed ≥2 hours vs IR</li>
    <li>Cmax reduced ≥25% vs IR</li>
    <li>AUC ≥70% of IR (bioavailability acceptable)</li>
    <li>Food effect &lt;2-fold on Cmax</li>
</ul>

<div class="warning-box">
    <strong>When to Skip Animal PK:</strong>
    <ul>
        <li>If going compounding-only route (503A)</li>
        <li>If dissolution data looks excellent</li>
        <li>If budget is limited - can do human PK directly (with physician oversight)</li>
    </ul>
    <p>Animal PK de-risks but isn't strictly required for compounding.</p>
</div>

<hr>

<h2>Phase 4B: Human PK Testing (Recommended Alternative to Animal)</h2>

<div class="timeline">
    <strong>Duration:</strong> 2 weeks | <strong>Cost:</strong> <span class="cost">$1,500-4,000</span>
</div>

<div class="success-box">
    <h4 style="margin-top: 0;">Why Human Self-Testing Makes Sense Here</h4>
    <table>
        <tr>
            <th>Factor</th>
            <th>Dog PK Study</th>
            <th>Physician Self-Test</th>
        </tr>
        <tr>
            <td>Cost</td>
            <td>$30,000 - $50,000</td>
            <td>$1,500 - $4,000</td>
        </tr>
        <tr>
            <td>Timeline</td>
            <td>6-10 weeks</td>
            <td>2 weeks</td>
        </tr>
        <tr>
            <td>Relevance</td>
            <td>Dogs ≠ humans (different GI physiology)</td>
            <td>Direct human data</td>
        </tr>
        <tr>
            <td>Minoxidil safety data</td>
            <td>Requires vet oversight</td>
            <td>45+ years of human safety data at these doses</td>
        </tr>
    </table>
    <p><strong>Key point:</strong> Minoxidil is already FDA-approved for human oral use. The physician isn't testing a new drug - he's testing a new <em>formulation</em> of a known, safe drug at established therapeutic doses.</p>
</div>

<h3>4B.1 Pre-Requisites for Human PK Testing</h3>

<ul class="checklist">
    <li>Dissolution testing completed and meets target profile</li>
    <li>Assay confirms 95-105% of label claim</li>
    <li>Content uniformity passes (AV ≤ 15.0)</li>
    <li>Physician volunteer is healthy, normotensive (BP > 100/60)</li>
    <li>Physician has informed themselves of risks and consents</li>
    <li>Someone else knows the protocol in case of emergency</li>
    <li>BP cuff and pulse oximeter available</li>
    <li>Bioanalytical lab identified for minoxidil plasma assay</li>
</ul>

<h3>4B.2 Fasted PK Study Protocol</h3>

<div class="phase-box">
    <h4 style="margin-top: 0;">Day 1: Fasted Condition</h4>
    <table>
        <tr>
            <th>Time</th>
            <th>Action</th>
            <th>Notes</th>
        </tr>
        <tr>
            <td>Night before</td>
            <td>No food after 10 PM</td>
            <td>Water permitted</td>
        </tr>
        <tr>
            <td>7:30 AM</td>
            <td>Baseline blood draw (T=0)</td>
            <td>Before dosing</td>
        </tr>
        <tr>
            <td>7:30 AM</td>
            <td>Check BP and HR</td>
            <td>Record baseline vitals</td>
        </tr>
        <tr>
            <td>8:00 AM</td>
            <td>Take 1 capsule (8.5 mg) with 240 mL water</td>
            <td>Note exact time</td>
        </tr>
        <tr>
            <td>8:30 AM</td>
            <td>Blood draw (T=0.5h)</td>
            <td></td>
        </tr>
        <tr>
            <td>9:00 AM</td>
            <td>Blood draw (T=1h) + vitals</td>
            <td>Check BP/HR</td>
        </tr>
        <tr>
            <td>10:00 AM</td>
            <td>Blood draw (T=2h) + vitals</td>
            <td>Check BP/HR</td>
        </tr>
        <tr>
            <td>11:00 AM</td>
            <td>Blood draw (T=3h)</td>
            <td></td>
        </tr>
        <tr>
            <td>12:00 PM</td>
            <td>Blood draw (T=4h) + vitals</td>
            <td>Can eat light meal after this draw</td>
        </tr>
        <tr>
            <td>2:00 PM</td>
            <td>Blood draw (T=6h)</td>
            <td></td>
        </tr>
        <tr>
            <td>4:00 PM</td>
            <td>Blood draw (T=8h) + vitals</td>
            <td></td>
        </tr>
        <tr>
            <td>8:00 PM</td>
            <td>Blood draw (T=12h) - final</td>
            <td>End of Day 1</td>
        </tr>
    </table>
    <p><strong>Total blood draws:</strong> 9 samples (approximately 45 mL total blood)</p>
</div>

<h3>4B.3 Washout Period</h3>

<div class="warning-box">
    <p><strong>Days 2-7: Washout Period</strong></p>
    <p>Wait at least 5-7 days between fasted and fed studies. Minoxidil half-life is ~4 hours, but its effects on blood pressure can persist longer. A full week ensures complete washout.</p>
</div>

<h3>4B.4 Fed PK Study Protocol</h3>

<div class="phase-box">
    <h4 style="margin-top: 0;">Day 8: Fed Condition (High-Fat Breakfast)</h4>

    <p><strong>FDA Standard High-Fat Breakfast:</strong></p>
    <ul>
        <li>2 eggs fried in butter</li>
        <li>2 strips of bacon</li>
        <li>2 slices of toast with butter</li>
        <li>4 oz hash browns</li>
        <li>8 oz whole milk</li>
    </ul>
    <p><em>Total: ~800-1000 calories, ~50% from fat</em></p>

    <table>
        <tr>
            <th>Time</th>
            <th>Action</th>
            <th>Notes</th>
        </tr>
        <tr>
            <td>7:30 AM</td>
            <td>Baseline blood draw (T=0) + vitals</td>
            <td>Before breakfast</td>
        </tr>
        <tr>
            <td>7:30-8:00 AM</td>
            <td>Eat high-fat breakfast</td>
            <td>Finish within 30 minutes</td>
        </tr>
        <tr>
            <td>8:30 AM</td>
            <td>Take 1 capsule (8.5 mg) with 240 mL water</td>
            <td>30 min after completing breakfast</td>
        </tr>
        <tr>
            <td>9:00 AM</td>
            <td>Blood draw (T=0.5h)</td>
            <td></td>
        </tr>
        <tr>
            <td>9:30 AM</td>
            <td>Blood draw (T=1h) + vitals</td>
            <td></td>
        </tr>
        <tr>
            <td>10:30 AM</td>
            <td>Blood draw (T=2h) + vitals</td>
            <td></td>
        </tr>
        <tr>
            <td>11:30 AM</td>
            <td>Blood draw (T=3h)</td>
            <td></td>
        </tr>
        <tr>
            <td>12:30 PM</td>
            <td>Blood draw (T=4h) + vitals</td>
            <td></td>
        </tr>
        <tr>
            <td>2:30 PM</td>
            <td>Blood draw (T=6h)</td>
            <td></td>
        </tr>
        <tr>
            <td>4:30 PM</td>
            <td>Blood draw (T=8h) + vitals</td>
            <td></td>
        </tr>
        <tr>
            <td>8:30 PM</td>
            <td>Blood draw (T=12h) - final</td>
            <td></td>
        </tr>
    </table>
    <p><strong>Total blood draws:</strong> 9 samples (approximately 45 mL total blood)</p>
</div>

<h3>4B.5 Safety Monitoring</h3>

<div class="danger-box">
    <h4 style="margin-top: 0;">Safety Stopping Rules</h4>
    <p><strong>STOP the study and seek medical care if:</strong></p>
    <ul>
        <li>Systolic BP drops &gt;30 mmHg from baseline</li>
        <li>Systolic BP falls below 90 mmHg</li>
        <li>Heart rate exceeds 120 bpm sustained (&gt;5 minutes)</li>
        <li>Severe dizziness or lightheadedness</li>
        <li>Chest pain, palpitations, or shortness of breath</li>
        <li>Any concerning symptoms</li>
    </ul>
    <p><strong>Expected mild effects (not reasons to stop):</strong></p>
    <ul>
        <li>Mild decrease in BP (5-15 mmHg) - expected</li>
        <li>Slight increase in HR (5-15 bpm) - expected</li>
        <li>Mild lightheadedness when standing quickly</li>
    </ul>
</div>

<h3>4B.6 Blood Sample Handling</h3>

<table>
    <tr>
        <th>Step</th>
        <th>Specification</th>
    </tr>
    <tr>
        <td>Collection tubes</td>
        <td>K2-EDTA (purple top) - 5 mL per draw</td>
    </tr>
    <tr>
        <td>Centrifugation</td>
        <td>Within 30 minutes, 3000 rpm x 10 min, 4°C</td>
    </tr>
    <tr>
        <td>Plasma separation</td>
        <td>Transfer plasma to labeled cryovials (minimum 1 mL)</td>
    </tr>
    <tr>
        <td>Storage</td>
        <td>-20°C (short term) or -80°C (preferred)</td>
    </tr>
    <tr>
        <td>Shipping</td>
        <td>Ship on dry ice to bioanalytical lab</td>
    </tr>
    <tr>
        <td>Labeling</td>
        <td>Subject ID, Date, Timepoint (e.g., "FASTED-T2H")</td>
    </tr>
</table>

<h3>4B.7 Success Criteria</h3>

<table>
    <tr>
        <th>Parameter</th>
        <th>Target (Fasted)</th>
        <th>Acceptable Fed Variation</th>
    </tr>
    <tr>
        <td>Cmax</td>
        <td>6-10 ng/mL</td>
        <td>Fed should not exceed 15 ng/mL</td>
    </tr>
    <tr>
        <td>Tmax</td>
        <td>2-4 hours</td>
        <td>Fed may be 1-3 hours (faster is OK if Cmax controlled)</td>
    </tr>
    <tr>
        <td>Food effect ratio</td>
        <td>Baseline</td>
        <td>Fed Cmax should be &lt;150% of fasted Cmax</td>
    </tr>
    <tr>
        <td>Duration above 1.62 ng/mL</td>
        <td>&gt;8 hours</td>
        <td>Similar in fed state</td>
    </tr>
</table>

<div class="warning-box">
    <h4>If Food Effect is Too High (&gt;150%)</h4>
    <p>If fed Cmax is &gt;150% of fasted Cmax, the lipid matrix may be releasing too fast with food. Consider reformulating:</p>
    <ul>
        <li>Increase Compritol 888 ATO percentage</li>
        <li>Decrease PEG 6000 (pore former)</li>
        <li>Add calcium stearate or carnauba wax as release retardant</li>
    </ul>
</div>

<hr>

<h2>Specific Test Specifications</h2>

<h3>Dissolution Testing Specifications</h3>

<div class="phase-box">
    <h4 style="margin-top: 0;">Test to Order: USP Dissolution Test</h4>
    <table>
        <tr>
            <th>Parameter</th>
            <th>Specification</th>
        </tr>
        <tr>
            <td><strong>Test Name</strong></td>
            <td>USP &lt;711&gt; Dissolution Test</td>
        </tr>
        <tr>
            <td><strong>Apparatus</strong></td>
            <td>USP Apparatus 2 (Paddle)</td>
        </tr>
        <tr>
            <td><strong>Paddle speed</strong></td>
            <td>50 rpm</td>
        </tr>
        <tr>
            <td><strong>Temperature</strong></td>
            <td>37.0 ± 0.5°C</td>
        </tr>
        <tr>
            <td><strong>Volume</strong></td>
            <td>900 mL</td>
        </tr>
        <tr>
            <td><strong>Replicates</strong></td>
            <td>6 units per batch (n=6)</td>
        </tr>
    </table>
</div>

<h4>Fasted State Dissolution (Primary Test)</h4>
<table>
    <tr>
        <th>Parameter</th>
        <th>Specification</th>
    </tr>
    <tr>
        <td><strong>Medium</strong></td>
        <td>0.1N HCl (pH 1.2) for first 2 hours, then phosphate buffer pH 6.8</td>
    </tr>
    <tr>
        <td><strong>Alternative (simpler)</strong></td>
        <td>Phosphate buffer pH 6.8 throughout (if pH-independent release confirmed)</td>
    </tr>
    <tr>
        <td><strong>Timepoints</strong></td>
        <td>1, 2, 4, 6, 8, 12 hours</td>
    </tr>
    <tr>
        <td><strong>Detection</strong></td>
        <td>UV spectrophotometry at 281 nm or HPLC</td>
    </tr>
</table>

<h4>Target Dissolution Profile</h4>
<table>
    <tr>
        <th>Timepoint</th>
        <th>Target Release (%)</th>
        <th>Acceptable Range</th>
    </tr>
    <tr>
        <td>1 hour</td>
        <td>15-20%</td>
        <td>10-25%</td>
    </tr>
    <tr>
        <td>4 hours</td>
        <td>40-50%</td>
        <td>35-55%</td>
    </tr>
    <tr>
        <td>8 hours</td>
        <td>65-75%</td>
        <td>60-80%</td>
    </tr>
    <tr>
        <td>12 hours</td>
        <td>&gt;80%</td>
        <td>&gt;75%</td>
    </tr>
</table>

<h4>Fed State Dissolution (Food Effect Test)</h4>
<table>
    <tr>
        <th>Parameter</th>
        <th>Specification</th>
    </tr>
    <tr>
        <td><strong>Medium Option 1</strong></td>
        <td>FeSSIF (Fed State Simulated Intestinal Fluid) - contains bile salts and lecithin</td>
    </tr>
    <tr>
        <td><strong>Medium Option 2 (cheaper)</strong></td>
        <td>Phosphate buffer pH 6.8 + 0.5% SLS (sodium lauryl sulfate)</td>
    </tr>
    <tr>
        <td><strong>Medium Option 3 (simplest)</strong></td>
        <td>Whole milk (3.25% fat) - surprisingly predictive</td>
    </tr>
    <tr>
        <td><strong>Timepoints</strong></td>
        <td>1, 2, 4, 6, 8 hours</td>
    </tr>
    <tr>
        <td><strong>Acceptance</strong></td>
        <td>4-hour release should be &lt;1.5x fasted state 4-hour release</td>
    </tr>
</table>

<h4>What to Tell the Lab</h4>
<div class="success-box">
    <p><strong>When ordering dissolution testing, specify:</strong></p>
    <ol>
        <li>"USP Apparatus 2 (paddle), 50 rpm, 900 mL, 37°C"</li>
        <li>"Medium: Phosphate buffer pH 6.8" (or specify 0.1N HCl → pH 6.8 switch)</li>
        <li>"Timepoints: 1, 2, 4, 6, 8, 12 hours"</li>
        <li>"Detection: UV at 281 nm" (or HPLC if they prefer)</li>
        <li>"n=6 units per batch"</li>
        <li>"Report % dissolved at each timepoint with mean and SD"</li>
    </ol>
    <p><strong>Estimated cost:</strong> $200-500 per dissolution profile (6 units, 6 timepoints)</p>
</div>

<hr>

<h3>Bioanalytical Testing Specifications (Human PK)</h3>

<div class="phase-box">
    <h4 style="margin-top: 0;">Test to Order: Plasma Minoxidil Assay</h4>
    <table>
        <tr>
            <th>Parameter</th>
            <th>Specification</th>
        </tr>
        <tr>
            <td><strong>Test Name</strong></td>
            <td>Minoxidil plasma concentration by LC-MS/MS</td>
        </tr>
        <tr>
            <td><strong>Method</strong></td>
            <td>Liquid chromatography-tandem mass spectrometry</td>
        </tr>
        <tr>
            <td><strong>Sample matrix</strong></td>
            <td>Human plasma (K2-EDTA)</td>
        </tr>
        <tr>
            <td><strong>LLOQ (Lower limit of quantification)</strong></td>
            <td>≤0.5 ng/mL (ideally ≤0.1 ng/mL)</td>
        </tr>
        <tr>
            <td><strong>Calibration range</strong></td>
            <td>0.5 - 50 ng/mL (or 0.1 - 50 ng/mL)</td>
        </tr>
        <tr>
            <td><strong>Sample volume required</strong></td>
            <td>200-500 µL plasma per sample</td>
        </tr>
    </table>
</div>

<h4>Samples to Submit</h4>
<table>
    <tr>
        <th>Study</th>
        <th>Timepoints</th>
        <th>Number of Samples</th>
    </tr>
    <tr>
        <td>Fasted PK</td>
        <td>0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours</td>
        <td>9 samples</td>
    </tr>
    <tr>
        <td>Fed PK</td>
        <td>0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours</td>
        <td>9 samples</td>
    </tr>
    <tr>
        <td><strong>Total</strong></td>
        <td></td>
        <td><strong>18 samples</strong></td>
    </tr>
</table>

<h4>What to Tell the Bioanalytical Lab</h4>
<div class="success-box">
    <p><strong>When ordering plasma minoxidil assay, specify:</strong></p>
    <ol>
        <li>"Minoxidil quantification by LC-MS/MS"</li>
        <li>"Matrix: Human plasma, K2-EDTA"</li>
        <li>"LLOQ required: ≤0.5 ng/mL"</li>
        <li>"Calibration range: 0.5-50 ng/mL"</li>
        <li>"Total samples: 18"</li>
        <li>"Report individual concentrations in ng/mL"</li>
        <li>"Include QC sample results"</li>
    </ol>
    <p><strong>Estimated cost:</strong> $75-150 per sample = $1,350-2,700 for 18 samples</p>
</div>

<h4>Bioanalytical Lab Options</h4>
<table>
    <tr>
        <th>Lab</th>
        <th>Location</th>
        <th>Est. Cost/Sample</th>
        <th>Notes</th>
    </tr>
    <tr>
        <td>Absorption Systems (Pharmaron)</td>
        <td>Exton, PA</td>
        <td>$100-150</td>
        <td>High quality; may have minoxidil method validated</td>
    </tr>
    <tr>
        <td>QPS Holdings</td>
        <td>Newark, DE</td>
        <td>$75-125</td>
        <td>Good for small studies</td>
    </tr>
    <tr>
        <td>Frontage Laboratories</td>
        <td>Exton, PA</td>
        <td>$60-100</td>
        <td>Often competitive pricing</td>
    </tr>
    <tr>
        <td>ICON Bioanalytical Labs</td>
        <td>Whitesboro, NY</td>
        <td>$80-120</td>
        <td>Large capacity</td>
    </tr>
    <tr>
        <td>University research labs</td>
        <td>Various</td>
        <td>$50-80</td>
        <td>Cheapest but may need method development</td>
    </tr>
</table>

<h4>PK Parameters to Calculate</h4>
<p>Ask the lab to calculate (or calculate yourself using Phoenix WinNonlin, PKSolver, or Excel):</p>
<table>
    <tr>
        <th>Parameter</th>
        <th>Description</th>
        <th>Target</th>
    </tr>
    <tr>
        <td>Cmax</td>
        <td>Maximum observed concentration</td>
        <td>6-10 ng/mL (fasted)</td>
    </tr>
    <tr>
        <td>Tmax</td>
        <td>Time to reach Cmax</td>
        <td>2-4 hours</td>
    </tr>
    <tr>
        <td>AUC0-12</td>
        <td>Area under curve, 0-12 hours</td>
        <td>Record value</td>
    </tr>
    <tr>
        <td>AUC0-∞</td>
        <td>Area under curve, extrapolated to infinity</td>
        <td>Record value</td>
    </tr>
    <tr>
        <td>t½</td>
        <td>Elimination half-life</td>
        <td>~4 hours (known for minoxidil)</td>
    </tr>
    <tr>
        <td>Food effect ratio</td>
        <td>Fed Cmax / Fasted Cmax</td>
        <td>&lt;1.5 (i.e., &lt;50% increase)</td>
    </tr>
</table>

<hr>

<h2>Phase 5: Compounding Setup</h2>

<div class="timeline">
    <strong>Duration:</strong> 2-4 weeks | <strong>Cost:</strong> <span class="cost">$1,000-3,000</span>
</div>

<h3>5.1 Pharmacy Selection</h3>

<ul class="checklist">
    <li>Identify 2-3 candidate compounding pharmacies</li>
    <li>Confirm lipid matrix / melt granulation capability</li>
    <li>Confirm 503A or 503B registration</li>
    <li>Request references / quality certifications</li>
    <li>Select pharmacy partner</li>
</ul>

<h3>5.2 Technology Transfer</h3>

<ul class="checklist">
    <li>Provide formulation protocol to pharmacy</li>
    <li>Review process with their pharmacist</li>
    <li>Pharmacy makes qualification batch</li>
    <li>Run dissolution on pharmacy's batch</li>
    <li>Confirm results match your development batches</li>
</ul>

<h3>5.3 Prescriber Setup</h3>

<ul class="checklist">
    <li>Identify 1-3 dermatologists willing to prescribe off-label</li>
    <li>Provide them with: formulation info, dosing rationale, safety data</li>
    <li>Establish prescription workflow with pharmacy</li>
    <li>Create patient consent/information document</li>
</ul>

<div class="success-box">
    <strong>Phase 5 Exit Criteria:</strong>
    <ul>
        <li>Pharmacy can successfully compound the formulation</li>
        <li>Pharmacy's batch matches your dissolution profile</li>
        <li>At least one prescribing physician ready</li>
        <li>Patient information materials ready</li>
    </ul>
</div>

<hr>

<h2>Dissolution Testing Providers</h2>

<h3>Budget Options (Fast & Cheap)</h3>

<div class="provider-card">
    <h4>1. University Pharmaceutical Sciences Labs</h4>
    <p><strong>Cost:</strong> $50-150 per dissolution run</p>
    <p><strong>Turnaround:</strong> 1-2 weeks</p>
    <p><strong>Pros:</strong> Cheapest option; may provide consulting</p>
    <p><strong>Cons:</strong> Slower; may have scheduling constraints</p>
    <p><strong>How to find:</strong> Contact pharmacy schools with dissolution equipment (most do)</p>
    <p><strong>Examples:</strong></p>
    <ul>
        <li>University of Michigan College of Pharmacy</li>
        <li>University of Texas at Austin College of Pharmacy</li>
        <li>University of North Carolina Eshelman School of Pharmacy</li>
        <li>Rutgers Ernest Mario School of Pharmacy</li>
        <li>Any local pharmacy school with equipment access</li>
    </ul>
</div>

<div class="provider-card">
    <h4>2. PCCA (Professional Compounding Centers of America)</h4>
    <p><strong>Cost:</strong> $200-500 per dissolution profile</p>
    <p><strong>Turnaround:</strong> 1-2 weeks</p>
    <p><strong>Pros:</strong> Compounding-focused; understands your application</p>
    <p><strong>Cons:</strong> May prioritize member pharmacies</p>
    <p><strong>Contact:</strong> pccarx.com | 800-331-2498</p>
</div>

<div class="provider-card">
    <h4>3. Contract Testing Labs (Mid-Range)</h4>
    <p><strong>Cost:</strong> $300-800 per dissolution profile</p>
    <p><strong>Turnaround:</strong> 5-10 business days</p>
    <table>
        <tr>
            <th>Lab</th>
            <th>Location</th>
            <th>Website</th>
        </tr>
        <tr>
            <td>Analytical Food Laboratories (AFL)</td>
            <td>Grand Prairie, TX</td>
            <td>afltexas.com</td>
        </tr>
        <tr>
            <td>Intertek Pharmaceutical Services</td>
            <td>Multiple locations</td>
            <td>intertek.com</td>
        </tr>
        <tr>
            <td>Element Materials Technology</td>
            <td>Multiple locations</td>
            <td>element.com</td>
        </tr>
        <tr>
            <td>SGS Life Sciences</td>
            <td>Multiple locations</td>
            <td>sgs.com</td>
        </tr>
        <tr>
            <td>Eurofins Lancaster Labs</td>
            <td>Lancaster, PA</td>
            <td>eurofins.com</td>
        </tr>
    </table>
</div>

<h3>Full-Service CROs (More Expensive but Comprehensive)</h3>

<div class="provider-card">
    <h4>4. Specialty Pharma CROs</h4>
    <p><strong>Cost:</strong> $1,000-3,000 per study</p>
    <p><strong>Turnaround:</strong> 2-4 weeks</p>
    <p><strong>Pros:</strong> Full service; can do dissolution + assay + stability</p>
    <table>
        <tr>
            <th>CRO</th>
            <th>Specialty</th>
            <th>Website</th>
        </tr>
        <tr>
            <td>Absorption Systems (Pharmaron)</td>
            <td>Dissolution, PK</td>
            <td>absorption.com</td>
        </tr>
        <tr>
            <td>Gateway Analytical</td>
            <td>Physical characterization</td>
            <td>gatewayanalytical.com</td>
        </tr>
        <tr>
            <td>Particle Sciences (Lubrizol)</td>
            <td>Formulation support</td>
            <td>particlesciences.com</td>
        </tr>
        <tr>
            <td>Metrics Contract Services</td>
            <td>Full CMC package</td>
            <td>metricscontractservices.com</td>
        </tr>
        <tr>
            <td>Catalent</td>
            <td>Full service CDMO</td>
            <td>catalent.com</td>
        </tr>
    </table>
</div>

<h3>DIY Option</h3>

<div class="provider-card">
    <h4>5. Buy/Rent Equipment</h4>
    <p><strong>Cost:</strong> $5,000-15,000 (used dissolution apparatus) or $500-1,000/month rental</p>
    <p><strong>Pros:</strong> Unlimited testing; fast iteration</p>
    <p><strong>Cons:</strong> Need HPLC/UV for analysis; space requirements</p>
    <p><strong>Equipment sources:</strong></p>
    <ul>
        <li>eBay / LabX (used equipment)</li>
        <li>Agilent, Sotax, Distek (new equipment)</li>
        <li>Excedr (equipment leasing)</li>
    </ul>
</div>

<h3>Recommended Approach</h3>

<div class="success-box">
    <p><strong>Start with a university lab or PCCA</strong> for initial dissolution testing ($50-200/run). If you need more than 5-10 runs, consider a contract lab for efficiency.</p>
    <p><strong>Budget estimate for dissolution testing:</strong></p>
    <ul>
        <li>Development phase (10-15 runs): $500-2,000</li>
        <li>Fed-state testing (3-5 runs): $150-500</li>
        <li>Stability testing (10-15 runs over 6 months): $500-1,500</li>
        <li><strong>Total: $1,150-4,000</strong></li>
    </ul>
</div>

<hr>

<h2>Animal PK Study Providers</h2>

<p>If you decide to do the dog PK study:</p>

<table>
    <tr>
        <th>CRO</th>
        <th>Location</th>
        <th>Estimated Cost</th>
        <th>Notes</th>
    </tr>
    <tr>
        <td>Absorption Systems (Pharmaron)</td>
        <td>Exton, PA</td>
        <td>$35-50K</td>
        <td>Excellent for oral PK; IVIVC expertise</td>
    </tr>
    <tr>
        <td>QPS Holdings</td>
        <td>Newark, DE</td>
        <td>$30-45K</td>
        <td>Good for small studies</td>
    </tr>
    <tr>
        <td>Covance (Labcorp Drug Development)</td>
        <td>Madison, WI</td>
        <td>$40-60K</td>
        <td>Large CRO; may have minimums</td>
    </tr>
    <tr>
        <td>Charles River</td>
        <td>Multiple</td>
        <td>$40-55K</td>
        <td>Large CRO; comprehensive</td>
    </tr>
    <tr>
        <td>ICON (PRA Health Sciences)</td>
        <td>Multiple</td>
        <td>$35-50K</td>
        <td>Good for crossover designs</td>
    </tr>
    <tr>
        <td>Frontage Laboratories</td>
        <td>Exton, PA</td>
        <td>$25-40K</td>
        <td>Often more competitive pricing</td>
    </tr>
</table>

<hr>

<h2>Master Checklist: Before Human Use</h2>

<div class="danger-box">
    <h3 style="margin-top: 0;">CRITICAL REQUIREMENTS</h3>
    <ul class="checklist">
        <li class="critical">Dissolution meets target profile (20-25% 1h, 50-60% 4h, >85% 12h)</li>
        <li class="critical">Assay: 95-105% of label claim</li>
        <li class="critical">Content uniformity: AV ≤ 15.0</li>
        <li class="critical">1-month accelerated stability: no significant change</li>
        <li class="critical">Compounding pharmacy can reproduce your results</li>
        <li class="critical">Licensed physician willing to prescribe</li>
        <li class="critical">Patient information/consent document prepared</li>
    </ul>
</div>

<h3>Complete Pre-Human Checklist</h3>

<table>
    <tr>
        <th>#</th>
        <th>Task</th>
        <th>Status</th>
        <th>Required?</th>
    </tr>
    <tr>
        <td>1</td>
        <td>Finalize formula composition</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>2</td>
        <td>Source all excipients (pharma grade)</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>3</td>
        <td>Source minoxidil API (USP grade, with COA)</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>4</td>
        <td>Make development batches (3 minimum)</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>5</td>
        <td>Dissolution testing - fasted media</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>6</td>
        <td>Dissolution testing - fed state media</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>7</td>
        <td>Iterate formula if dissolution off-spec</td>
        <td>☐</td>
        <td>If needed</td>
    </tr>
    <tr>
        <td>8</td>
        <td>Assay testing (HPLC)</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>9</td>
        <td>Content uniformity testing</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>10</td>
        <td>Physical testing (weight, hardness, friability)</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>11</td>
        <td>Place samples on accelerated stability</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>12</td>
        <td>1-month accelerated stability results</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>13</td>
        <td>DSC testing for polymorphism</td>
        <td>☐</td>
        <td>Recommended</td>
    </tr>
    <tr>
        <td>14</td>
        <td>Dog PK study (fed/fasted)</td>
        <td>☐</td>
        <td>Optional (recommended)</td>
    </tr>
    <tr>
        <td>15</td>
        <td>Identify compounding pharmacy partner</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>16</td>
        <td>Technology transfer to pharmacy</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>17</td>
        <td>Pharmacy qualification batch</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>18</td>
        <td>Dissolution on pharmacy's batch</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>19</td>
        <td>Identify prescribing physician(s)</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>20</td>
        <td>Create patient information document</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>21</td>
        <td>Establish prescription workflow</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
    <tr>
        <td>22</td>
        <td>Document all development work</td>
        <td>☐</td>
        <td>Yes</td>
    </tr>
</table>

<hr>

<h2>Recommended Sequence</h2>

<div class="phase-box">
<pre style="font-family: monospace; white-space: pre;">
WEEK 1-2: Source materials, make first batches
    │
    ▼
WEEK 2-3: Dissolution testing (iterate if needed)
    │
    ▼
WEEK 3-4: QC testing (assay, CU, physical)
    │
    ├──────────────────────────────────┐
    ▼                                  ▼
WEEK 4+: Stability testing         WEEK 4-5: Pharmacy outreach
(runs in parallel)                     │
    │                                  ▼
    │                              WEEK 5-6: Tech transfer
    │                                  │
    ▼                                  ▼
WEEK 8: 1-month stability          WEEK 6-7: Pharmacy qualification
         results                       │
    │                                  ▼
    └──────────────┬───────────────────┘
                   │
                   ▼
            WEEK 8-10: Ready for first patient
                   │
                   ▼
            OPTIONAL: Dog PK study (parallel track, 4-6 weeks)
</pre>
</div>

<hr>

<h2>Budget Summary</h2>

<table>
    <tr>
        <th>Item</th>
        <th>Low Estimate</th>
        <th>High Estimate</th>
    </tr>
    <tr>
        <td>Excipients & API (development quantities)</td>
        <td>$500</td>
        <td>$1,500</td>
    </tr>
    <tr>
        <td>Dissolution testing (15-20 runs)</td>
        <td>$1,000</td>
        <td>$4,000</td>
    </tr>
    <tr>
        <td>Assay & CU testing</td>
        <td>$500</td>
        <td>$2,000</td>
    </tr>
    <tr>
        <td>Physical testing</td>
        <td>$200</td>
        <td>$500</td>
    </tr>
    <tr>
        <td>Stability testing (6 months)</td>
        <td>$1,500</td>
        <td>$4,000</td>
    </tr>
    <tr>
        <td>DSC/XRD testing</td>
        <td>$300</td>
        <td>$1,000</td>
    </tr>
    <tr>
        <td>Pharmacy tech transfer</td>
        <td>$500</td>
        <td>$2,000</td>
    </tr>
    <tr>
        <td>Contingency (20%)</td>
        <td>$900</td>
        <td>$3,000</td>
    </tr>
    <tr style="font-weight: bold; background-color: #e6f4ea;">
        <td>TOTAL (without dog PK)</td>
        <td>$5,400</td>
        <td>$18,000</td>
    </tr>
    <tr>
        <td>Dog PK study (optional)</td>
        <td>$25,000</td>
        <td>$50,000</td>
    </tr>
    <tr style="font-weight: bold; background-color: #e6f4ea;">
        <td>TOTAL (with dog PK)</td>
        <td>$30,400</td>
        <td>$68,000</td>
    </tr>
</table>

<hr>

<h2>Key Decision Points</h2>

<div class="warning-box">
    <h4>Decision 1: After Initial Dissolution Testing</h4>
    <ul>
        <li><strong>If dissolution meets spec:</strong> Proceed to QC and stability</li>
        <li><strong>If dissolution too fast:</strong> Increase Compritol, decrease PEG, re-test</li>
        <li><strong>If dissolution too slow:</strong> Decrease Compritol, increase PEG, re-test</li>
        <li><strong>If can't get it right after 4 iterations:</strong> Consider pivoting to MUPS</li>
    </ul>
</div>

<div class="warning-box">
    <h4>Decision 2: After 1-Month Accelerated Stability</h4>
    <ul>
        <li><strong>If stable:</strong> Proceed to compounding setup</li>
        <li><strong>If dissolution slows >15%:</strong> Add annealing step, re-test</li>
        <li><strong>If assay drops >5%:</strong> Investigate degradation, may need formulation change</li>
    </ul>
</div>

<div class="warning-box">
    <h4>Decision 3: Dog PK Study?</h4>
    <ul>
        <li><strong>Do it if:</strong> You plan to eventually seek FDA approval, or want to de-risk</li>
        <li><strong>Skip it if:</strong> Budget limited, going compounding-only, dissolution looks excellent</li>
    </ul>
</div>

<hr>

<h2>Appendix A: Safety Assumptions & Monitoring Protocol</h2>

<div class="info-box">
    <h4 style="margin-top: 0;">Purpose of This Appendix</h4>
    <p>This section documents the safety rationale underlying our PK targets and specifies what we will monitor in human PK studies. It addresses the question: <em>"Why do you believe 6-10 ng/mL is safe?"</em></p>
</div>

<h3>A.1 Cardiac Activity Threshold: Evidence Basis</h3>

<table>
    <tr>
        <th>Source</th>
        <th>Finding</th>
        <th>Citation</th>
    </tr>
    <tr>
        <td><strong>Loniten FDA Label</strong></td>
        <td>Cardiovascular effects (tachycardia, fluid retention) observed at antihypertensive doses (10-40 mg/day), which produce Cmax >20 ng/mL</td>
        <td>Loniten Prescribing Information, FDA Reference ID: 3839461, Rev. October 2015</td>
    </tr>
    <tr>
        <td><strong>Fleishaker 1989</strong></td>
        <td>At 2.5 mg single dose, Cmax = 16.8 ± 7.83 ng/mL with minimal hemodynamic effects in healthy volunteers</td>
        <td>J Clin Pharmacol. 1989;29(2):162-7. PMID: 2715373</td>
    </tr>
    <tr>
        <td><strong>Vano-Galvan 2021</strong></td>
        <td>1,404 patients on 0.25-5 mg/day (estimated Cmax 2-15 ng/mL); 98.3% continued treatment; no serious cardiovascular events</td>
        <td>J Am Acad Dermatol. 2021;84(6):1644-1651. PMID: 33259872</td>
    </tr>
    <tr>
        <td><strong>Clinical Consensus</strong></td>
        <td>Cardiovascular effects become clinically relevant when Cmax approaches or exceeds ~20 ng/mL; below this, effects are generally mild and manageable</td>
        <td>Multiple reviews: Randolph 2021, Jimenez-Cauhe 2020</td>
    </tr>
</table>

<h3>A.2 What We Are Claiming vs. Not Claiming</h3>

<div class="success-box">
    <h4 style="margin-top: 0;">What We ARE Claiming</h4>
    <ul>
        <li>Cmax of 6-10 ng/mL is within the range used safely in thousands of patients</li>
        <li>Cmax is a reasonable <strong>proxy</strong> for peak pharmacodynamic burden</li>
        <li>Reducing Cmax vs. IR minoxidil should reduce peak-related cardiovascular effects</li>
        <li>ER formulation allows higher total daily dose while keeping Cmax below threshold</li>
    </ul>
</div>

<div class="warning-box">
    <h4 style="margin-top: 0;">What We Are NOT Claiming</h4>
    <ul>
        <li>We are NOT claiming Cmax alone predicts all safety outcomes</li>
        <li>We are NOT claiming tissue accumulation (e.g., cardiac tissue) is being measured or controlled</li>
        <li>We are NOT claiming safety in patients with pre-existing cardiac conditions, renal impairment, or those on concurrent antihypertensives</li>
        <li>We are NOT claiming the 20 ng/mL threshold is an absolute safety boundary—it is a practical guideline based on clinical experience</li>
    </ul>
</div>

<h3>A.3 Human PK Safety Monitoring Protocol</h3>

<p>During the physician self-test PK study, the following will be monitored:</p>

<table>
    <tr>
        <th>Parameter</th>
        <th>Method</th>
        <th>Frequency</th>
        <th>Alert Threshold</th>
    </tr>
    <tr>
        <td><strong>Blood Pressure</strong></td>
        <td>Automated cuff (seated, 5 min rest)</td>
        <td>Baseline, 1h, 2h, 4h, 8h post-dose</td>
        <td>SBP drop >30 mmHg or SBP <90 mmHg</td>
    </tr>
    <tr>
        <td><strong>Heart Rate</strong></td>
        <td>Pulse oximeter or manual</td>
        <td>Baseline, 1h, 2h, 4h, 8h post-dose</td>
        <td>HR >120 bpm sustained >5 min</td>
    </tr>
    <tr>
        <td><strong>Symptoms</strong></td>
        <td>Subject self-report</td>
        <td>Continuous during study day</td>
        <td>Dizziness, palpitations, chest discomfort, SOB</td>
    </tr>
    <tr>
        <td><strong>Weight/Edema</strong></td>
        <td>Scale; ankle inspection</td>
        <td>Baseline, Day 2, Day 8</td>
        <td>Weight gain >2 kg; visible ankle edema</td>
    </tr>
    <tr>
        <td><strong>ECG (Optional)</strong></td>
        <td>12-lead or single-lead device</td>
        <td>Baseline, 2h post-dose</td>
        <td>New arrhythmia, significant ST changes</td>
    </tr>
</table>

<h3>A.4 Factors That Increase Individual Risk</h3>

<p>The following patient factors may increase sensitivity to minoxidil's cardiovascular effects and should be considered for future patient selection:</p>

<ul>
    <li><strong>Pre-existing hypotension</strong> (baseline SBP <100 mmHg)</li>
    <li><strong>Concurrent antihypertensive medications</strong> (additive BP lowering)</li>
    <li><strong>Renal impairment</strong> (reduced clearance → higher exposure)</li>
    <li><strong>High sodium intake</strong> (exacerbates fluid retention)</li>
    <li><strong>History of pericardial effusion</strong> (rare but documented with high-dose minoxidil)</li>
    <li><strong>Congestive heart failure</strong> (contraindicated per Loniten label)</li>
</ul>

<div class="danger-box">
    <h4 style="margin-top: 0;">Initial PK Study Exclusions</h4>
    <p>For the physician self-test, the volunteer should NOT have:</p>
    <ul>
        <li>Baseline SBP <100 mmHg or DBP <60 mmHg</li>
        <li>Current use of any antihypertensive medication</li>
        <li>Known cardiac disease or arrhythmia</li>
        <li>Renal impairment (eGFR <60)</li>
    </ul>
</div>

<hr>

<h2>Appendix B: Formal Go/No-Go Decision Gates</h2>

<div class="phase-box">
    <h4 style="margin-top: 0;">Gate Structure: Primary Path → Hard Gates → Backup → Parallel Legal</h4>
    <p>This structure ensures disciplined decision-making at each stage.</p>
</div>

<table>
    <tr>
        <th>Gate</th>
        <th>Metric</th>
        <th>PASS Criteria</th>
        <th>FAIL Action</th>
    </tr>
    <tr>
        <td><strong>Gate 1: Dissolution</strong></td>
        <td>In-vitro release profile</td>
        <td>15-25% (1h), 40-55% (4h), >75% (12h)</td>
        <td>Reformulate (adjust Compritol/PEG); max 4 iterations then evaluate MUPS</td>
    </tr>
    <tr>
        <td><strong>Gate 2: Stability</strong></td>
        <td>1-month accelerated (40°C/75% RH)</td>
        <td>Dissolution within ±10% of T0; Assay >95%</td>
        <td>Add annealing step; if still fails, evaluate MUPS</td>
    </tr>
    <tr style="background-color: #fff3cd;">
        <td><strong>Gate 3: Food Effect (HARD GATE)</strong></td>
        <td>Fed vs. Fasted Cmax ratio</td>
        <td><strong>Fed Cmax ≤150% of Fasted Cmax</strong></td>
        <td><strong>PIVOT TO MUPS BACKUP</strong></td>
    </tr>
    <tr>
        <td><strong>Gate 4: Human PK</strong></td>
        <td>Fasted Cmax, Tmax</td>
        <td>Cmax 5-12 ng/mL; Tmax 1.5-5h</td>
        <td>Reformulate to adjust release rate</td>
    </tr>
    <tr>
        <td><strong>Gate 5: Safety</strong></td>
        <td>Vital signs in PK study</td>
        <td>No stopping rule triggered</td>
        <td>Reduce dose; investigate cause</td>
    </tr>
</table>

<div class="warning-box">
    <h4 style="margin-top: 0;">Gate 3 Is the Hard Gate</h4>
    <p><strong>Food effect is the primary technical risk for lipid matrix formulations.</strong> If high-fat meal increases Cmax by >50% vs. fasted state, the formulation is not suitable for real-world use where patients may not consistently fast.</p>
    <p><strong>Decision rule:</strong> If Gate 3 fails, do not attempt to reformulate lipid matrix. Pivot immediately to MUPS (ethylcellulose-coated pellets), which has more predictable food effect behavior.</p>
</div>

<div class="success-box">
    <h4 style="margin-top: 0;">Parallel Track: IPR Filing</h4>
    <p><strong>IPR proceeds regardless of formulation outcome.</strong> Patent invalidity arguments apply to any ER minoxidil product, not just lipid matrix. File IPR within 6 months of starting development to maximize leverage.</p>
</div>

<hr>

<p><em>Document prepared: February 5, 2026</em></p>
<p><em>Last updated: February 5, 2026 - Added Safety Appendix and Formal Decision Gates per GPT review feedback</em></p>

</body>
</html>
